DOCSLIB.ORG

Therapeutic Uses of Metronidazole and Its Side Effects: an Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Uses of Metronidazole and Its Side Effects: an Update European Review for Medical and Pharmacological Sciences 2019; 23: 397-401 Therapeutic uses of metronidazole and its side effects: an update A. HERNÁNDEZ CERUELOS, L.C. ROMERO-QUEZADA, J.C. RUVALCABA LEDEZMA, L. LÓPEZ CONTRERAS Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo, Circuito Ex Hacienda, Pachuca de Soto Hidalgo, México Abstract. – OBJECTIVE: Metronidazole is Introduction an antibiotic widely used in different medical conditions such as trichomoniasis, amoebia- sis, and giardiasis among others. Its use has Metronidazole is a synthetic antibiotic derivat- been associated with toxicity; however, it is not ized from azomycin, a nitroimidazole produced well characterized. In this review, we discuss by the genera Actinobacteria and Proteobacteria. the different therapeutic uses of metronidazole In 1959, this compound was used for trichomonia- and its side effects in order to aid future inves- sis treatment, an infection caused by the protozoan tigation in this field. MATERIALS AND METHODS: Relevant infor- Trichomonas vaginalis. Further, metronidazole has mation, original research articles, clinical tri- been effective against dysentery and liver abscess als, and reviews were collected from PubMed to produced by the intestinal protozoan parasite, En- know the state of the art of the different thera- tamoeba histolytica. It also was efficacious against peutic uses of metronidazole and the reported Giardia lamblia, another intestinal parasite that side effects. 1 RESULTS: causes malabsorption and epigastric pain . Metroni- Metronidazole was used by the dazole is available as orally, intravenously, vaginally first time in 1959, to treat an infection caused by Trichomonas vaginalis; subsequently, new ther- and rectally presentations, although the most clin- apeutic properties were discovered. Nowadays, ically used is the oral presentation. Its oral dosage Metronidazole is used to treat infections caused forms of 250 or 500 mg are rapidly absorbed and by Bacteroides, Fusobacteria and Clostridia, ro- distributed almost to the entire body. The liver is the sacea, oral and dental infections, bone and joint main organ responsible for metabolizing metronida- infections, gynecologic infections, endocarditis, zole, where this is hydroxylated, acetylated and or septicemia, and respiratory tract infections. It al- conjugated with glucuronides. The metabolites are so can be used to treat Crohn´s disease or even 2-4 like prophylaxis, before surgical procedures. finally excreted mainly by the kidneys . Metronidazole is well tolerated with mild to mod- Metronidazole was introduced in 1959 for erate side effects such as nausea, abdominal trichomoniasis treatment; however, subsequent- pain, and diarrhea. Nevertheless, serious neu- ly, new pharmacological properties were uncov- rotoxicity, optic neuropathy, peripheral neurop- ered5. Due to the high cost and long time needed athy, and encephalopathy have been reported in for research and development of novel therapeutic rare cases. Their genotoxic effects observed in animal models are controversial in humans. molecules, exploring new uses of existing drugs 6,7 CONCLUSIONS: The therapeutic use of metro- is a possible solution to treat infectious diseases . nidazole had increased worldwide. Even though In this review, we recapitulate the current clini- it is widely used, metronidazole has been asso- cal uses of metronidazole and discuss their side ciated with neurotoxicity and genotoxicity; how- effects. ever, its side effects are not well established. Conversely, its veterinary use is restricted in Pharmacodynamics some countries because of its tumor associa- tion. Subsequently, further studies are needed The mechanism of action of metronidazole to discover the secure use of metronidazole and has not been fully elucidated. However, its nitro describe new usages for this drug. group reduction by anaerobic organisms appears to be responsible for the cytotoxic and antimicro- Key Words: bial effects. The mechanism described for this Metronidazole, Therapeutic uses, Side effects. drug is summarized here: Corresponding Author: Luilli López Contreras, Ph.D; e-mail: [email protected] 397 A. Hernández Ceruelos, L.C. Romero-Quezada, J.C. Ruvalcaba Ledezma, L. López Contreras Metronidazole crosses the membrane of the cell in combination with bismuth and tetracycline for target by passive diffusion; then, its nitro group is two weeks is highly effective for H. pylori era- reduced to nitro radicals by ferredoxin or flavodoxin. dication. Dosage may vary from 200 to 500 mg The selectivity of metronidazole for anaerobic three or five times daily. Metronidazole also has or microaerophilic microorganisms is due to the been combined with bismuth and amoxicillin or redox potential of their electron transport compo- with acid suppression regimens15-17. nents, which are responsible for nitro group re- duction and generate toxic metabolites. Clostridium Difficile These metabolites such as N-(2-hydroxyethyl) C. difficile colitis is a major cause of nosocomial oxamic acid and acetamide can react with DNA infections, causing morbidity and mortality in pa- and form adducts with guanosine1,5. tients. Its treatment is based on oral metronidazole, 500 mg three times a day for 10-14 days18-20. Antibiotic and Antiparasitic Uses Metronidazole is usually, very effective to treat Anaerobic Infections infections caused by anaerobic or microaerophilic Metronidazole is also effective against anaero- microorganisms, such as Trichomonas vaginalis, bic bacteria (for example, Bacteroides fragilis) in Giardia lamblia, Entamoeba histolytica, Clostri- combination with other antibiotics such as cefa- dium difficile, Helicobacter pylori,among others1. zolin, cefuroxime, ceftriaxone, quinolone, cefta- zidime, cefepime, carbapenems, piperacillin or Amoebiasis tazobactam depending on the infection type. Me- Amoebiasis is an infection caused by the protozo- tronidazole dosage varies in anaerobic infections; an Entamoeba histolytica that can result in amebic however, 500 mg administered intravenously colitis or amebic liver abscess. Optimal treatment, every 8 h is the most common dose used13,21. usually effective for intestinal or hepatic infections by E. histolytica, includes three daily oral doses of Crohn’s Disease 750 mg of metronidazole for 5 or 10 days8-10. Crohn’s disease is a chronic inflammatory bowel disease, which has been hypothesized, is Giardiasis the result of an abnormal immune response to the Giardia lamblia is the most common intesti- gut microbiome in susceptible subjects. Metroni- nal parasite as the etiological agent of diarrheal dazole is used for the treatment of Crohn’s disease around the world; its treatment is based on 250 and its effectiveness has been evaluated in several mg of the drug thrice daily for 5 to 7 days11. clinical trials, suggesting that metronidazole has therapeutic benefits against the symptoms, such Trichomoniasis as perianal discharge and pain. However, control- Trichomonas vaginalis is a protozoan parasite led clinical trials are needed to establish the effi- responsible for one of the most sexually transmit- cacy of metronidazole for Crohn´s disease13,22. ted diseases, and its management includes a 2 g single dose of metronidazole. However, if the sin- Surgical Prophylaxis gle dose fails, the treatment can be administered Infections after surgical procedures contribu- during 7 days12,13. te to higher rates of mortality; however, a single dose of 500 mg metronidazole reduces the risk of Bacterial Vaginosis postoperative anaerobic infections when is used Metronidazole is useful to treat some bacterial as a prophylactic treatment in appendicitis, but infections. 500 mg are administered orally twice also is used in prophylactic treatment in surgical a day for a week. There is a second scheme con- procedures for the colon, head, and neck13,23-24. sisting of a single dose of 2 g of metronidazole, mainly used to treat Gardnerella vaginalis. A gel Rosacea presentation of 0.75% metronidazole, administe- Rosacea is a cutaneous disease of uncertain red intravaginally twice a day for five days is also etiology characterized by flushing, erythema, pa- effective for bacterial vaginosis13,14. pules, pustules and telangiectasia that affect the cheeks, nose, eyes, chin and forehead26. There Helicobacter Pylori are various treatments available for rosacea, but H. pylori causes peptic ulcers disease and it is topical metronidazole gel and azelaic acid appe- associated with stomach cancer. Metronidazole ar to be effective and safe according to multiple 398 Therapeutic uses of metronidazole and its side effects: an update clinical trials. 200 mg of metronidazole, admini- der metabolic activation39. Also, it has been re- stered orally twice a day for 12 weeks, is effica- ported, that metronidazole can induce an increase cious when tetracycline is not effective in rosacea in chromosomal aberrations and chromatid and treatment25-27. isochromatic breaks in the cell of patients treated with therapeutic doses of metronidazole40. Adverse Effects of Metronidazole In a study41 where patients were treated with me- Metronidazole is well tolerated with mild to mo- tronidazole 4 hours before surgery to remove colon derate side effects such as nausea, abdominal pain, tumors, a high concentration of the drug and its hy- and diarrhea. Serious neurotoxicity, optic neuro- droxyl metabolite were found inside the lesion and pathy, peripheral neuropathy, and encephalopathy
Load more

Recommended publications
  • Skin Probiotics ACCELERATING INNOVATION
    ACCELERATING INNOVATION James Madison University technologies are available for licensing through its nonprofit affiliate, James Madison Innovations, Inc. Skin Probiotics Inventors: Reid Harris and Kevin Minbiole Department: Biology and Chemistry Overview Research Funding and Source: National Science Foundation James Madison University inventors have filed a patent Years of Development: 4 years application on a helpful bacterium that could potentially be Technology Readiness: Research Development used as a therapy for human skin fungus such as athlete’s foot. Patent Status: U.S. patent pending 20110002891 The JMU inventors have developed a potential process to Contact: Mary Lou Bourne, Director of Technology Transfer deliver a helpful microbe, Janthinobacterium Lividum to the James Madison University skin using a pharmaceutically acceptable carrier. The microbe Phone: (540)568-2865 E-mail: [email protected] has been shown to suppress bacterial and fungal growth on animals and in lab demonstrations. Tech Transfer and Business Model Infections can be a problem for a wide array of hosts. For JMI is interested in identifying an existing company or example, there are a variety of infections, such as bacterial, entrepreneur interested in commercializing the technology viral and/or fungal infections, that affect a large percentage of either under an exclusive or a non-exclusive license. A the human population. Tricophyton rubrum, the fungus that small company or entrepreneur could further develop the causes athlete’s foot, is responsible for approximately 46% to technology, possibly using SBIR or STTR funding. 72% of cutaneous and nail mycoses worldwide. Onychomycosis, a common and persistent fungal infection, is Market and Competition In 2008, the U.S.
    [Show full text]
  • Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
    processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Options
    Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment.
    [Show full text]
  • Natural Products As Potential Antiparasitic Drugs
    Natural Products as potential antiparasitic drugs OLIVER KAYSER1, ALBRECHT F. KIDERLEN2, SIMON L. CROFT3 1Freie Universität Berlin Institut für Pharmazie, Pharmazeutische Biotechnologie Kelchstraße 31, 12169 Berlin, Germany 2Robert Koch-Institut Nordufer 20 13353 Berlin, Germany 3London School of Hygiene and Tropical Medicine Department of Infectious and Tropical Diseases Keppel Street London, WC1E 7HT, United Kingdom ABSTRACT: Pharmaceutical research in natural products represents a major strategy for discovering and developing new drugs. The use of medicinal plants for the treatment of parasitic diseases is well known and documented since ancient times e.g. by the use of Cinchona succiruba (Rubiaceae) as an antimalarial. This chapter provides a comprehensive review of the latest results in the field of antiparasitic drug development from biologic sources (plants, bacteria, fungi and marine organisms) focussing on the treatment of protozoal infections (Plasmodium, Leishmania, Trypanosoma spp.). The status of validated in vitro and in vivo assays is reviewed, discussing their different features, problems and limitations. Because of the high number of natural products tested against the aforesaid protozoa in the last years, we limit the discussion to lignans, phenolics, terpenoids, and alkaloids as defined natural product classes. The review also covers essential research topics of recent publications on specific natural products (e.g. licochalcone A, benzyl- and naphthylisoquinoline alkaloids, and artemisinin) and gives an outlook to semi- synthetic approaches of drugs already introduced in clinics or in clinical trial studies. 1. INTRODUCTION The fascination of natural products, mostly as used as a preparation from a plant with known medicinal properties, goes back to ancient times. The discovery of pure compounds as active principles in plants was first described at the beginning of the 19th century, and the art of exploiting natural products has become part of the molecular sciences.
    [Show full text]
  • Antiparasitic Properties of Cardiovascular Agents Against Human Intravascular Parasite Schistosoma Mansoni
    pharmaceuticals Article Antiparasitic Properties of Cardiovascular Agents against Human Intravascular Parasite Schistosoma mansoni Raquel Porto 1, Ana C. Mengarda 1, Rayssa A. Cajas 1, Maria C. Salvadori 2 , Fernanda S. Teixeira 2 , Daniel D. R. Arcanjo 3 , Abolghasem Siyadatpanah 4, Maria de Lourdes Pereira 5 , Polrat Wilairatana 6,* and Josué de Moraes 1,* 1 Research Center for Neglected Diseases, Guarulhos University, Praça Tereza Cristina 229, São Paulo 07023-070, SP, Brazil; [email protected] (R.P.); [email protected] (A.C.M.); [email protected] (R.A.C.) 2 Institute of Physics, University of São Paulo, São Paulo 05508-060, SP, Brazil; [email protected] (M.C.S.); [email protected] (F.S.T.) 3 Department of Biophysics and Physiology, Federal University of Piaui, Teresina 64049-550, PI, Brazil; [email protected] 4 Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran; [email protected] 5 CICECO-Aveiro Institute of Materials & Department of Medical Sciences, University of Aveiro, 3810-193 Aveiro, Portugal; [email protected] 6 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand * Correspondence: [email protected] (P.W.); [email protected] (J.d.M.) Citation: Porto, R.; Mengarda, A.C.; Abstract: The intravascular parasitic worm Schistosoma mansoni is a causative agent of schistosomiasis, Cajas, R.A.; Salvadori, M.C.; Teixeira, a disease of great global public health significance. Praziquantel is the only drug available to F.S.; Arcanjo, D.D.R.; Siyadatpanah, treat schistosomiasis and there is an urgent demand for new anthelmintic agents.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity
    molecules Review Antiprotozoal and Antitumor Activity of Natural Polycyclic Endoperoxides: Origin, Structures and Biological Activity Valery M. Dembitsky 1,2,*, Ekaterina Ermolenko 2, Nick Savidov 1, Tatyana A. Gloriozova 3 and Vladimir V. Poroikov 3 1 Centre for Applied Research, Innovation and Entrepreneurship, Lethbridge College, 3000 College Drive South, Lethbridge, AB T1K 1L6, Canada; [email protected] 2 A.V. Zhirmunsky National Scientific Center of Marine Biology, 17 Palchevsky Str., 690041 Vladivostok, Russia; [email protected] 3 Institute of Biomedical Chemistry, 10 Pogodinskaya Str., 119121 Moscow, Russia; [email protected] (T.A.G.); [email protected] (V.V.P.) * Correspondence: [email protected]; Tel.: +1-403-320-3202 (ext. 5463); Fax: +1-888-858-8517 Abstract: Polycyclic endoperoxides are rare natural metabolites found and isolated in plants, fungi, and marine invertebrates. The purpose of this review is a comparative analysis of the pharmacological potential of these natural products. According to PASS (Prediction of Activity Spectra for Substances) estimates, they are more likely to exhibit antiprotozoal and antitumor properties. Some of them are now widely used in clinical medicine. All polycyclic endoperoxides presented in this article demonstrate antiprotozoal activity and can be divided into three groups. The third group includes endoperoxides, which show weak antiprotozoal activity with a reliability of up to 70%, and this group includes only 1.1% of metabolites. The second group includes the largest number of endoperoxides, Citation: Dembitsky, V.M.; which are 65% and show average antiprotozoal activity with a confidence level of 70 to 90%. Lastly, Ermolenko, E.; Savidov, N.; the third group includes endoperoxides, which are 33.9% and show strong antiprotozoal activity with Gloriozova, T.A.; Poroikov, V.V.
    [Show full text]
  • The Role of Antiparasitc Drugs and Steroids in Covid-19 Treatment
    Research, Society and Development, v. 10, n. 8, e39510817300, 2021 (CC BY 4.0) | ISSN 2525-3409 | DOI: http://dx.doi.org/10.33448/rsd-v10i8.17300 The role of antiparasitc drugs and steroids in Covid-19 treatment O papel das drogas antiparasitárias e corticóides no tratamento da Covid-19 El papel de los antiparasitos y los esteroides en el tratamiento del Covid-19 Received: 06/17/2021 | Reviewed: 06/25/2021 | Accept: 07/03/2021 | Published: 07/14/2021 Luciano Barreto Filho ORCID: https://orcid.org/0000-0002-1508-4812 Faculdade de Odontologida do Recife, Brazil E-mail: [email protected] Paulo Reis Melo Júnior ORCID: https://orcid.org/0000-0001-9926-5348 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Guilherme Marinho Sampaio ORCID: https://orcid.org/0000-0003-4441-7601 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Gabriel Henrique Queiroz Oliveira ORCID:https://orcid.org/0000-0002-7795-3964 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Hadassa Fonsêca Da Silva ORCID: https://orcid.org/0000-0002-9432-9522 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Sandra Sayão Maia ORCID: https://orcid.org/0000-0001-6808-9775 Faculdade de Odontologia do Recife, Brazil E-mail: [email protected] Abstract Background: COVID-19 has emerged as a pandemic that spread throughout the world in less than 6 months, leaving hundred thousand deaths behind. Surprisingly, old drug arsenal has now been applied as an option of treatment. Objective: The aim of this article was to accomplish a literature review concerning the antiparasitic chloroquine, ivermectin, nitazoxanide; as well as glucocorticoids as possible therapeutic agents to be applied in patients with COVID-19 in Brazilian hospitals.
    [Show full text]
  • Essential Oils and Bioactive Components Against Arthritis: a Novel Perspective on Their Therapeutic Potential
    plants Review Essential Oils and Bioactive Components against Arthritis: A Novel Perspective on Their Therapeutic Potential Mariangela Marrelli * , Valentina Amodeo, Maria Rosaria Perri, Filomena Conforti y and Giancarlo Statti y Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy; [email protected] (V.A.); [email protected] (M.R.P.); fi[email protected] (F.C.); [email protected] (G.S.) * Correspondence: [email protected]; Tel.: +39-0984-493168; Fax: +39-0984-493107 These authors jointly supervised and contributed equally to this work. y Received: 18 August 2020; Accepted: 21 September 2020; Published: 23 September 2020 Abstract: Essential oils (EOs) are known to possess a number of beneficial properties. Their antimicrobial, anti-inflammatory, antioxidant, antidiabetic, and cancer-preventing activities have been extensively reported. Due to their wide use as food preservers and additives, as well as their use in agriculture, perfumes, and make-up products, these complex mixtures of volatile compounds have gained importance from a commercial point of view, not only in the pharmaceutical industry, but also in agronomic, food, cosmetic, and perfume industries. An analysis of the recent scientific literature allowed us to highlight the presence of an increasing number of studies on the potential antiarthritic properties of EOs and their main constituents, which seems to suggest a new interesting potential therapeutic application. The aim of this review is to examine the current knowledge on the beneficial effects of essential oils in the treatment of arthritic diseases, providing an overview of the reports on the in vivo and in vitro effects of EOs.
    [Show full text]
  • The Nitroimidazole Family of Drugs
    Br J Vener Dis: first published as 10.1136/sti.54.2.69 on 1 April 1978. Downloaded from British Journal of Venereal Diseases, 1978, 54, 69-71 Editorial The nitroimidazole family of drugs In 1955 an antibiotic complex isolated from a operative infection caused by susceptible anaerobes, strain of Streptomyces on the island of Reunion particularly in gynaecological surgery, appendi- was found by research workers of Rhone-Poulenc in cectomy, and colonic surgery. Paris to contain a trichomonacidal antibiotic- Real innovations in chemotherapy, such as azomycin. It had previously been isolated in Japan metronidazole, always attract attention from other (Maeda et al., 1953) and identified as 2-nitroimi- research groups. Although interest was slow to dazole (Ia see Table) (Nakamura, 1955). At the develop, research workers have sought analogous, time, and for some years after, this remarkably structurally-modified compounds which might afford simple compound defied synthesis, but it stimulated some advantage in clinical use-for example, the workers at Rhone-Poulenc to prepare and test greater potency, better tolerance and freedom from the activity of the more readily accessible isomeric side effects, a broader spectrum of action, a longer 5-nitroimidazoles (II). It was their good fortune in duration of action, or in some other characteristic. 1957 to find that these isomers were more active This effort has been concerned with important antiprotozoal agents than the natural product veterinary uses of 5-nitroimidazoles as well as the (Cosar and Julou, 1959). In a series of 150 related applications in human medicine. compounds, the one with a P-hydroxyethyl group Metronidazole has been a difficult target to in the 1-position gave the best compromise between improve upon, but several other drugs of this activity and toxicity and this brand of metroni- chemical family have been introduced to clinical dazole was introduced as Flagyl.
    [Show full text]
  • Review Rheumatological Patients Undergoing Immunosuppressive
    Review Rheumatological patients undergoing immunosuppressive treatments and parasitic diseases: a review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections S. Fabiani and F. Bruschi Department of Translational Research ABSTRACT Conclusions. Considering parasitic in- and New Technologies in Medicine and Objective. Nowadays, several po- fections as emerging and potentially se- Surgery, School of Infectious Diseases, tent immunosuppressive drugs are rious in their evolution, additional strat- Università di Pisa, Pisa, Italy available for patients with rheumato- egies for the prevention, careful screen- Silvia Fabiani, MD logic disorders. In general, these treat- ing and follow-up, with a high level of Fabrizio Bruschi, MD ments are acceptably well tolerated. suspicion, identification, and pre-emp- Please address correspondence to: Nevertheless, in patients with rheu- tive therapy are necessary in candidate Fabrizio Bruschi, matic diseases, who are taking immu- patients for biological agents. Scuola Medica, Via Roma 55, nosuppressive drugs, an increased risk 56126 Pisa, Italy. of bacterial, viral and fungal, as well Introduction E-mail: [email protected] as parasitic infections, exists. Rationale Received on October 14, 2013; accepted Methods. We have reviewed literature, Immunosuppressive drugs, other than in revised form on February 18, 2014. on PubMed library, on the topic “par- corticosteroids (CS), are used in the Clin Exp Rheumatol 2014; 32: 587-596. asitic infections in rheumatic disease treatment of various rheumatologic con- © Copyright CLINICAL AND patients treated with immunosuppres- ditions to induce or maintain a remis- EXPERIMENTAL RHEUMATOLOGY 2014. sive drugs, including biological thera- sion, to reduce the frequency of flare pies”.
    [Show full text]
  • POS0555 the NATURAL COURSE of RHEUMATOID ARTHRITIS- Medications for RA Or for Comorbidities Including Adverse Events (Aes)
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2021-eular.2810 on 19 May 2021. Downloaded from 512 Scientific Abstracts Methods: We used a large Japanese administrative claims database con- Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., and Takeda structed by the Japan Medical Data Center (JMDC)2. Patients with the Inter- Pharmaceutical Co., Ltd., Consultant of: AbbVie GK, Bristol-Myers Squibb K.K., national Classification of Diseases 10th revision (ICD-10) codes for RA were Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Gilead Sciences enrolled at the first DMARDs prescription after no DMARDs prescription period Inc., Grant/research support from: AbbVie GK, and Asahi Kasei Corp., Astellas for 6-months (index date) in the period from 1/1/2012 to 12/31/2017. Patients who Pharma Inc., Ayumi Pharmaceutical Corporation, Bristol-Myers Squibb K.K., were observable for 12 months after the index date as a follow-up period were Chugai Pharmaceutical Co., Ltd. Daiichi-Sankyo, Inc., Eisai Co., Ltd., Mitsubishi included. Patients treated with CSs within the follow-up period were compared Tanabe Pharma Corporation., Nippon Kayaku Co., Ltd., Taisho Pharmaceutical with those without them (CS and non-CS group). The primary endpoint was Co., Ltd., and Takeda Pharmaceutical Co., Ltd. mean medical cost per patient in the 12-month follow-up period. The secondary DOI: 10.1136/annrheumdis-2021-eular.2805 endpoints were costs for drugs, treatments, and materials and the proportions of patients using the subcategories of each resource. Drugs were divided into POS0555 THE NATURAL COURSE OF RHEUMATOID ARTHRITIS- medications for RA or for comorbidities including adverse events (AEs).
    [Show full text]